Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Medicines Taskforce

- PMLiVE

Alzheimer’s Research UK calls for government action to address inequalities in dementia risk

The call comes as researchers presented findings demonstrating a link between socio-economic deprivation and higher dementia risk

- PMLiVE

Alzheimer’s Research UK welcomes ambitions for dementia set out in first women’s health strategy

The ten-year strategy follows the charity’s calls for action to tackle dementia’s disproportionate impact on women

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...

Wilmington Healthcare

- PMLiVE

NHS awarded George Cross for efforts shown during the COVID-19 pandemic

The George Cross is the UK’s highest civilian gallantry award and has only been given to a collective group twice before

- PMLiVE

UK government invests £175m to ‘supercharge’ clinical research

The £175m adds to the £200m in funding announced earlier this year to strengthen the national data infrastructure

- PMLiVE

Alzheimer’s Research UK supports government plans for clinical research

The charity has suggested creating a Dementia Medicines Taskforce in order to address diseases like Alzheimer's

- PMLiVE

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Wilmington Healthcare

- PMLiVE

LifeArc partners with UK Dementia Research Institute

Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

- PMLiVE

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

Wilmington Healthcare

- PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug

Those receiving the drug experienced a significantly slower decline than usual

- PMLiVE

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

There are no approved treatment options available for acute agitation related to dementia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links